Just to de-bunk nonsense posted elsewhere, it is good news for humanity that Paratek's new antibiotic looks like it's on the path toward approval. The more new antibiotics, the better. BUT: it's a tetracycline derivative:

Quote:

---

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines

---

http://www.streetinsider.com/Corporate+News/P...48521.html

This means that:
1) lots of people can't take it, because they're allergic to the cycline class of antibiotics
2) bacteria will eventually develop resistance

Also, the article talks about a "one pill a day" regimen.
Brilacidin is a ONE DOSE regimen. Which would you rather prescribe if you're a doctor -- one dose that absolutely ensures patient compliance, or hoping that people take the full course of pills on their own (and let's remember, non-compliance with drug regimen is one of the reasons why bacteria have acquired resistance to drugs)

So when someone inquires "Is CTIX losing the race?" in their bashing way, the answer is a resounding NO.